Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
emtricitabine + tenofovir disoproxil fumarate + raltegravir + losartan (Merck & Co.)
- Development stage
- Unknown
- Lead developer
- Felipe Garcia
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Emtricitabine + tenofovir disoproxil fumarate + raltegravir + losartan is a combination regimen investigated for the treatment of HIV-1 infection, specifically focusing on reducing lymphatic tissue fibrosis and chronic inflammation. The regimen consists of three antiretroviral agents—emtricitabine and tenofovir disoproxil fumarate (nucleoside/nucleotide reverse transcriptase inhibitors) and raltegravir (an integrase strand transfer inhibitor)—alongside losartan, an angiotensin II receptor blocker. While the antiretrovirals suppress viral replication, losartan is included for its anti-fibrotic properties to mitigate the residual immune damage that persists in patients on stable antiretroviral therapy. This specific combination was evaluated in a Phase 4 clinical trial (NCT01852942) led by researchers such as Felipe Garcia.
- Brand names
- TruvadaIsentress
- Other names
- emtricitabine + tenofovir disoproxil fumarate + MK-0518 + losartan
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseAGTR1 (Angiotensin II Type-1 receptor)Integrase allosteric pocket (HIV)POLG (Mitochondrial DNA polymerase gamma)
Beyond the preview
Go deeper on emtricitabine + tenofovir disoproxil fumarate + raltegravir + losartan (Merck & Co.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on emtricitabine + tenofovir disoproxil fumarate + raltegravir + losartan (Merck & Co.).